17:23:36 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-15 Årsstämma 2024
2024-04-25 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2023-10-04 08:30:00
Copenhagen, Denmark, 4 October  2023 - Brain+ A/S (Nasdaq First North: BRAINP)
  • A version 1.2 of CST-Therapist Companion with improved user features has been made available for municipal customers in Denmark

  • The update is based on user feedback following the introduction of CST-Therapist Companion v1.0 and the use of the product in dementia care practice

  • Brain+ retains its expectations to close additional sales contracts on CST-Therapist Companion in 2023

  • In parallel, Brain+ is developing CST-Therapist Companion v2.0 as a substantial product upgrade in terms of both CST content, user customization, adaptability, and functionality and with targeted release in Denmark in H1 2024

Brain+ informs that the company has released an updated version of its digital product, CST-Therapist Companion, which supports dementia coordinators deliver Cognitive Stimulation Therapy (CST) to people with dementia. CST is an evidence based and worldwide recommended non-pharmaceutical therapy that can reduce cognitive decline and improve social skills as well as quality-of-life for people with early Alzheimer's. Brain+' CST-Therapist Companion can reduce preparation time for CST therapists and support a more consistent high-quality delivery of the therapy.

CST-Therapist Companion was introduced to the Danish market in November 2022 as a minimum viable product (MVP) version. Based on feedback from users, the company has now made a number of product upgrades and released a new version 1.2 with improved user features and image quality, upgraded interface compatibility and extended licensing management.

Kim Baden-Kristensen, Brain+ CEO & Co-Founder "Continuous customer dialogue and feedback are important elements in our work to provide digital dementia therapy products that meet the needs of our users. We introduced the first version of CST-Therapist companion to the Danish municipalities about a year ago, and since then we have received valuable feedback to integrate into our product offering and experienced a significant increase in the awareness and acknowledgment of what CST can offer. In this context, our CST-Therapist Companion is seen as a valuable tool to support the implementation of CST for better treatment of people with dementia."

CST-Therapist Companion v2.0 in advanced development for H1 2024 release

Brain+' main development activities have been focused on the development of a substantial upgrade of the CST-Therapist Companion product. This upgrade is referred to as product version 2.0, as it represents a considerable increase in terms of the value delivered to dementia therapists offering CST.

CST-Therapist Companion v2.0 will include a substantially increased amount of high-quality and specialist validated CST content and features that enables customization of therapy sessions to adapt to the specific characteristics of a given group of people with dementia receiving the therapy. In this regard, the content in CST-Therapist Companion v2.0 can be adapted to provide the best possible CST support given the level of cognitive ability of the group, which can vary significantly in people with mild to moderate dementia. Other relevant characteristics to consider for the optimal therapy delivery are age, physical abilities, and social preferences.

CST-Therapist Companion v2.0 is in the final stage of development and a clinical usability trial of the product is planned to start in Denmark in October 2023. The trial will be conducted in collaboration with the main dementia care and CST specialists in Denmark with participation of six municipalities.

Brain+ expects to introduce a commercial version of CST-Therapist Companion v2.0 in H1 2024 following final product adjustments to be based on the outcome of the clinical trial.  

Contact Information

CEO and Co-founder: Kim Baden-Kristensen, + 45 31393317 (SMS), kim@brain-plus.com

Mission:  Bringing effective digitally-delivered dementia therapies to those in need, serving a million people with dementia, care-givers and clinicians by 2030